Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia.
Read More…
Industry, Sector and Symbol
Industry Commercial physical research
Sub-IndustryBiotechnology
SectorMedical
Phone302-498-6700
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.88 billion
Profitability
Miscellaneous
Employees1,367
Next Earnings Date10/29/2019 (Estimated)
OptionableOptionable
Incyte (NASDAQ:INCY) Frequently Asked Questions
What is Incyte's stock symbol?
Incyte trades on the NASDAQ under the ticker symbol "INCY."
How were Incyte's earnings last quarter?
Incyte Co. (NASDAQ:INCY) released its quarterly earnings data on Tuesday, July, 30th. The biopharmaceutical company reported $0.75 EPS for the quarter, beating the consensus estimate of $0.38 by $0.37. The biopharmaceutical company had revenue of $529.93 million for the quarter, compared to analysts' expectations of $498.57 million. Incyte had a return on equity of 17.10% and a net margin of 15.25%. Incyte's revenue was up 1.6% compared to the same quarter last year. During the same period last year, the firm posted $0.63 earnings per share. View Incyte's Earnings History.
When is Incyte's next earnings date?
What price target have analysts set for INCY?
21 brokers have issued 12-month target prices for Incyte's stock. Their predictions range from $74.00 to $111.00. On average, they expect Incyte's share price to reach $90.0588 in the next year. This suggests a possible upside of 6.7% from the stock's current price. View Analyst Price Targets for Incyte.
What is the consensus analysts' recommendation for Incyte?
21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Incyte in the last year. There are currently 10 hold ratings, 10 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Incyte.
What are Wall Street analysts saying about Incyte stock?
Here are some recent quotes from research analysts about Incyte stock:
- 1. According to Zacks Investment Research, "Incyte’s lead drug, Jakafi continues to maintain momentum for the company, as the underlying patient demand for the drug remains strong for both MF and PV. Incyte is working to expand the drug’s label into additional indications which should further boost sales. The FDA approval of Olumiant 2 mg, for which the company received a milestone payment from Lilly, is a positive. Shares have outperformed the industry in the past six months. However, pipeline setbacks continue to be a concern. The FDA’s extension of the review period of the sNDA for the label expansion of Jakafi to treat acute GVHD was disappointing. Earlier, Incyte suffered a setback with the failure of the phase III ECHO-301 study, evaluating epacadostat in combination with Keytruda." (4/29/2019)
- 2. Raymond James analysts commented, "We are reiterating our Strong Buy rating for Incyte. This morning, the company announced that the FDA has accepted for priority review its supplemental new drug application (sNDA) for Jakafi for the treatment of patients with steroid-refractory acute graft versus host disease (SR-aGVHD). The priority review grants a 6 month review period by the FDA, resulting in a PDUFA date of approximately March 25, 2019. Based on positive data from the REACH1 study, we remain confident regarding Incyte’s expansion into the steroid refractory GVHD market, which we estimate to be a ~$500 million market opportunity in the U.S." (10/25/2018)
- 3. Cantor Fitzgerald analysts commented, ". We are increasing our price target to $74 from $73 and reiterating our Neutral rating on INCY. At the ongoing ESMO, INCY provided updated Fight-202 results in cholangiocarcinoma, which looked superior to the previously disclosed initial data. Additionally, in a late-breaker presentation, Novartis (NVS, Not Covered) reported Phase II results from its MET inhibitor capmatinib in MET-mutated advanced non-small cell lung cancer (NSCLC) patients. Note that NVS received worldwide rights for capmatinib from INCY. NVS reported promising response rate data that compare favorably to earlier reported results from any MET inhibitors." (10/21/2018)
Has Incyte been receiving favorable news coverage?
Press coverage about INCY stock has been trending negative recently, InfoTrie reports. The research firm scores the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Incyte earned a coverage optimism score of -2.3 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Incyte.
Who are some of Incyte's key competitors?
Some companies that are related to Incyte include Iqvia (IQV), EXACT Sciences (EXAS), Icon (ICLR), Charles River Laboratories Intl. (CRL), PRA Health Sciences (PRAH), Exelixis (EXEL), Syneos Health (SYNH), BTG (BTGGF), Medpace (MEDP), National Research (NRC), Intrexon (XON), STARPHARMA HOLD/S (SPHRY), Sorrento Therapeutics (SRNE), Eloxx Pharmaceuticals (ELOX) and Pieris Pharmaceuticals (PIRS).
What other stocks do shareholders of Incyte own?
Who are Incyte's key executives?
Incyte's management team includes the folowing people:
- Mr. Hervé Hoppenot, Chairman, Pres & CEO (Age 59)
- Ms. Maria E. Pasquale, Exec. VP & Gen. Counsel
- Dr. Wenqing Yao, Exec. VP & Head of Discovery Chemistry (Age 56)
- Dr. Steven H. Stein, Exec. VP & Chief Medical Officer (Age 52)
- Ms. Christiana Stamoulis, Exec. VP & CFO (Age 48)
Who are Incyte's major shareholders?
Incyte's stock is owned by a number of of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (9.04%), BlackRock Inc. (6.95%), Price T Rowe Associates Inc. MD (3.56%), Invesco Ltd. (2.42%), UBS Asset Management Americas Inc. (1.86%) and Nuveen Asset Management LLC (1.03%). Company insiders that own Incyte stock include Barry P Flannelly, Bros Advisors Lp Baker, David W Gryska, Eric H Siegel, Herve Hoppenot, Jean Jacques Bienaime, Paul A Friedman, Paul Trower, Paula J Swain, Reid M Huber, Steven H Stein, Vijay K Iyengar and Yao Wenqing. View Institutional Ownership Trends for Incyte.
Which institutional investors are selling Incyte stock?
INCY stock was sold by a variety of institutional investors in the last quarter, including Manning & Napier Group LLC, BlackRock Inc., JPMorgan Chase & Co., Pictet Asset Management Ltd., Banco Santander S.A., Russell Investments Group Ltd., Allianz Asset Management GmbH and Jacobs Levy Equity Management Inc.. Company insiders that have sold Incyte company stock in the last year include Barry P Flannelly, Jean Jacques Bienaime, Paul A Friedman, Paul Trower, Paula J Swain, Steven H Stein and Yao Wenqing. View Insider Buying and Selling for Incyte.
Which institutional investors are buying Incyte stock?
INCY stock was bought by a variety of institutional investors in the last quarter, including Invesco Ltd., Nuveen Asset Management LLC, Renaissance Technologies LLC, Bessemer Group Inc., Vanguard Group Inc., First Trust Advisors LP, Bank of New York Mellon Corp and Marshall Wace North America L.P.. Company insiders that have bought Incyte stock in the last two years include Bros Advisors Lp Baker, Herve Hoppenot and Jean Jacques Bienaime. View Insider Buying and Selling for Incyte.
How do I buy shares of Incyte?
Shares of INCY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Incyte's stock price today?
One share of INCY stock can currently be purchased for approximately $84.42.
How big of a company is Incyte?
Incyte has a market capitalization of $18.16 billion and generates $1.88 billion in revenue each year. The biopharmaceutical company earns $109.49 million in net income (profit) each year or $0.82 on an earnings per share basis. Incyte employs 1,367 workers across the globe.View Additional Information About Incyte.
What is Incyte's official website?
How can I contact Incyte?
Incyte's mailing address is 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803. The biopharmaceutical company can be reached via phone at 302-498-6700 or via email at [email protected]
MarketBeat Community Rating for Incyte (NASDAQ INCY)
MarketBeat's community ratings are surveys of what our community members think about Incyte and other stocks. Vote "Outperform" if you believe INCY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INCY will underperform the S&P 500 over the long term. You may vote once every thirty days.
